Patent ID: 8652786

Claim:
A method for identifying a cancer in an individual that is susceptible to treatment with a Met tyrosine kinase inhibitor comprising: a. obtaining a fixed tissue sample comprising genomic DNA from an individual; b. contacting the tissue sample with a nucleic acid probe that comprises a nucleotide sequence consisting of TGGATAATTGTGTCTTTCTCTAG (SEQ ID NO: 3) and specifically hybridizes to Met gene DNA, and also comprises a fluorescent dye, to thereby form a hybridization complex comprising the nucleic acid probe and the Met gene DNA; c. detecting a fluorescent signal in the hybridization complex that is at least 8-fold higher than a fluorescent signal generated in a negative control sample which has an absence of Met gene amplification; and d. identifying the cancer as susceptible to treatment when the at least 8-fold higher fluorescent signal is detected in the hybridization complex.